General Information of Drug (ID: DM54MOP)

Drug Name
4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
242623
CAS Number
CAS 3656-02-8
TTD Drug ID
DM54MOP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [2]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [3]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [6]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [2]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [2]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [8]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin A2 (CCNA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-0183812 DMWYP86 Retinoblastoma 2D02.2 Terminated [10]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [1]
aloisine A DM5U1LN Discovery agent N.A. Investigative [11]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 Discovery agent N.A. Investigative [1]
MERIOLIN 8 DM0E95B Discovery agent N.A. Investigative [12]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y Discovery agent N.A. Investigative [13]
Purvalanol A DMNQ7TM Discovery agent N.A. Investigative [14]
MERIOLIN 1 DMJT93H Discovery agent N.A. Investigative [12]
MERIOLIN 4 DMIJMZQ Discovery agent N.A. Investigative [12]
MERIOLIN 6 DMW5AXC Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin A2 (CCNA2) TTAMQ62 CCNA2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [1]

References

1 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
4 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
5 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
6 Clinical pipeline report, company report or official report of BioTheryX.
7 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
8 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
9 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
10 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
11 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
12 Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51.
13 Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
14 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.